Psilocin

Discovery

R. Gordon Wasson's 1957 account of Psilocybe mushroom ceremonies in Oaxaca, Mexico brought the fungi to Western scientific attention. Albert Hofmann, working at Sandoz Laboratories in Basel, isolated psilocybin from cultivated Psilocybe mexicana in 1958^[10] and identified psilocin as its dephosphorylated active metabolite the following year.^[3] The structural kinship to serotonin — differing only in hydroxyl position and N,N-dimethylation — was immediately recognized.

Prohibition and the research gap

Sandoz marketed psilocybin as Indocybin for psychiatric research through the early 1960s, supporting studies in psychotherapy, end-of-life anxiety, and alcoholism. Rising non-medical use triggered regulatory backlash: psilocin and psilocybin entered US Schedule I on October 27, 1970, and the 1971 UN Convention on Psychotropic Substances extended prohibitions internationally. Clinical research effectively ceased for the next three decades.

Modern renaissance

The revival began with Griffiths et al.'s 2006 double-blind trial at Johns Hopkins, demonstrating that psilocybin occasions mystical-type experiences with lasting personal significance.^[4] Carhart-Harris et al.'s 2016 feasibility study showed rapid antidepressant effects in treatment-resistant depression,^[11] followed by the COMPASS Pathways Phase 2 trial published in the New England Journal of Medicine in 2022.^[12]

The FDA has since granted psilocybin two Breakthrough Therapy Designations, Oregon operationalized supervised therapeutic access in January 2023,^[13] and Australia became the first Western country to permit medical prescription.^[5] Formidable regulatory hurdles remain for full drug approval.^[14]

Structure

Psilocin belongs to the substituted tryptamine family — specifically the 4-hydroxytryptamine subclass. The parent scaffold is tryptamine, with psilocin carrying a hydroxyl group at the indole C4 position and two methyl groups on the terminal amine nitrogen. This makes it the dephosphorylated form of psilocybin and a close structural relative of bufotenin (5-hydroxy-DMT) and synthetic analogs such as 4-AcO-DMT and 4-HO-MET.

The structural relationship to serotonin is immediately apparent: both share the indole-ethylamine backbone, differing only in hydroxyl position (C4 versus C5) and the dimethylation of the amine. This similarity underlies psilocin's affinity for serotonin receptors.

Stereochemistry

Psilocin contains no stereocenters and is therefore achiral — no mirror-image forms exist. This contrasts with ergoline psychedelics such as LSD, where stereochemistry critically determines activity.

Physical properties and stability

Psilocin is a white to yellowish crystalline solid with a melting point of 173–176°C.^[15] It dissolves readily in methanol and ethanol but poorly in water. The compound is notably unstable: the hydroxyl group at C4 oxidizes rapidly on exposure to light, air, and moisture, producing the characteristic blue-green discoloration seen in bruised Psilocybe mushrooms. Storage requires low temperature, darkness, and inert atmosphere.

Natural occurrence

Psilocin occurs naturally in over 200 fungal species, primarily within Psilocybe, Panaeolus, Gymnopilus, Pluteus, and Conocybe. In intact mushroom tissue the predominant alkaloid is psilocybin (0.2–0.4% dry weight), which serves as a stable phosphorylated storage form.^[10] Dephosphorylation to psilocin occurs upon tissue damage — producing the bluing reaction — and upon ingestion, when enzymes in the gut cleave the phosphate group.

Mechanism of action

Psilocin produces its psychedelic effects by activating 5-HT₂A serotonin receptors in the brain. This mechanism is both necessary and sufficient: the selective 5-HT₂A blocker ketanserin completely abolishes all psychedelic effects, including visual hallucinations, altered consciousness, and changes in brain oscillation patterns.^[1][16]

Brain imaging confirms that psilocin produces dose-dependent occupancy of 5-HT₂A receptors — up to 72% at clinically relevant doses — with plasma psilocin levels tracking both receptor occupancy and subjective intensity in a linear relationship.^[17]

Psilocin also interacts with the SERT, a property unique among classical psychedelics and shared with MDMA. This interaction is thought to contribute a warmth and emotional openness that distinguishes the psilocin experience from the more analytical character of LSD.^[18]

A further layer of complexity comes from the discovery that intracellular 5-HT₂A receptors — those inside the cell, not on its surface — mediate the plasticity-promoting effects of psychedelics including psilocin.^[19] This explains why the brain's own serotonin does not trigger the same structural changes despite activating the same receptor type.

Modulatory interactions

The serotonin 1A receptor agonist buspirone reduces visual intensity and oceanic boundlessness scores, suggesting this receptor pathway partially dampens the visual dimension of the psychedelic state.^[16] Conversely, 5-HT₂C activation appears to cap the ceiling of 5-HT₂A-mediated responses — blocking 5-HT₂C increases the intensity of psilocin effects at higher doses.^[20]

Pharmacokinetics

Psilocybin is a pure prodrug: it converts almost entirely to psilocin before reaching the bloodstream, with enzymes in the gut wall cleaving the phosphate group.^[21] Only psilocin shows meaningful binding at serotonin receptors — the parent compound and downstream metabolites are pharmacologically inert.^[22]

Oral bioavailability averages approximately 53%, though individual variation is substantial.^[9] Peak plasma levels occur between 1.8 and 4 hours after ingestion,^[9][23] and free psilocin has an half-life of roughly 1.8 hours.^[24]

The primary metabolic enzyme is MAO-A, responsible for over 80% of hepatic psilocin clearance.^[25][9] Total clearance from the body substantially exceeds what the liver alone can account for, indicating significant metabolism in the gut, lungs, and other tissues.^[25]

Where it acts

Psilocin's most prominent neural effect is the disruption of the default mode network (default mode network) — the brain system that supports self-referential thought, internal narrative, and the sense of a continuous self. Under psilocin, the DMN loses its normal coordinated activity, and this desynchronization correlates directly with the experience of ego dissolution.^[26][27]

Alongside DMN disruption, psilocin produces a broadband reduction in organized brain oscillations — particularly alpha and beta waves — most pronounced in posterior cortex.^[28] This desynchronization is specifically 5-HT₂A-dependent, as ketanserin completely blocks the alpha-band changes.^[1]

Why it matters

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psilocin loosens the brain's top-down predictions — the ingrained assumptions that normally filter incoming sensory data — allowing bottom-up information to reshape entrenched patterns of thought.^[29] This framework connects the subjective experience of dissolved certainties and novel perception to the neural data showing increased entropy and decreased network organization.^[26]

Psilocin also qualifies as a psychoplastogen — a compound that rapidly promotes structural neural change. Two converging mechanisms drive this: direct potentiation of BDNF signaling via TrkB binding,^[2] and activation of intracellular serotonin receptors that trigger growth-related signaling cascades.^[19] These plasticity effects may explain why therapeutic benefits persist well beyond the drug's presence in the body.

Toxicity

Across more than 1,000 clinical administrations in 30 studies, a meta-analysis identified 9 serious adverse events total, with no suicide attempts during acute sessions.^[32]

Psychological risks

Tolerance & dependence

Psilocin produces no physical dependence and no withdrawal. Rapid tolerance develops through downregulation — effects diminish noticeably after a single dose, with near-complete tolerance within 3 days and full reset by approximately 7 days.^[8]

Complete cross-tolerance exists between psilocin, LSD, and mescaline, all mediated by the same 5-HT₂A downregulation mechanism.^[35][36] Clinical trial protocols typically require minimum 2-week intervals between doses.

A comprehensive abuse-potential analysis concluded that psilocin shows marginal reinforcing properties, is not reliably self-administered in animal models, produces no compulsive use pattern, and carries substantially lower abuse potential than most Schedule I substances.^[33]

Drug interactions

Lithium and mood stabilizers

Psilocybin administered to patients on concurrent SSRIs produced meaningful antidepressant improvements with no serious adverse events.^[37]

MAO inhibitors

Contraindications

Psilocin is internationally controlled under the 1971 United Nations Convention on Psychotropic Substances (Schedule I), requiring signatory nations to restrict its manufacture, trade, and possession. Most jurisdictions classify psilocin alongside psilocybin as a prohibited substance. Since 2023, two jurisdictions have created medical or supervised access pathways — a significant departure from five decades of blanket prohibition.

Analog and prodrug considerations

Psilocybin converts to psilocin in the body and is controlled identically in all jurisdictions. Synthetic 4-substituted tryptamine analogs (4-AcO-DMT, 4-HO-MET) may fall under analog legislation in jurisdictions with structural similarity provisions — notably the US Federal Analogue Act, which extends Schedule I/II controls to substantially similar compounds intended for human consumption. Australia's scheduling specifically covers psilocin and psilocybin rather than the broader 4-substituted tryptamine class.